Search Results
Feb 12, 2026, 07:00 ET Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort® Enteral Solution, Human Milk-Based Product in Japan
weight gain failure such as very low birth weight (VLBW) infants."The approval was supported by data from the pivotal Japan-based JASMINE Phase III clinical trial, a randomised, open-label, parallel-group comparison study in VLBW infants.This first-of-its kind approval set a new regulatory
More news about: Clinigen
Feb 12, 2026, 06:55 ET Core Natural Resources Reports Fourth Quarter 2025 Results
interest expense and depreciation, depletion and amortization, as adjusted for (ii) certain non-cash items, such as loss on debt extinguishment and (iii) other adjustments, such as stock-based compensation and Merger-related expenses. Adjusted EBITDA may also be adjusted for items that may not reflect
More news about: Core Natural Resources
Feb 12, 2026, 06:45 ET TELUS reports strong and industry leading operational and financial results for the fourth quarter and full year 2025; establishes compelling and industry-best 2026 financial targets
subscriber growth; and (iii) higher external revenues in TELUS Digital inclusive of favourable foreign exchange rates. These factors were partially offset by: (i) mobile phone ARPU declining at a decelerating rate; (ii) lower business-to-business (B2B) data services revenue; (iii) lower agriculture and
More news about: TELUS Corporation
Feb 12, 2026, 06:45 ET TELUS reports strong and industry leading operational and financial results for the fourth quarter and full year 2025; establishes compelling and industry-best 2026 financial targets
subscriber growth; and (iii) higher external revenues in TELUS Digital inclusive of favourable foreign exchange rates. These factors were partially offset by: (i) mobile phone ARPU declining at a decelerating rate; (ii) lower business-to-business (B2B) data services revenue; (iii) lower agriculture and
More news about: TELUS Corporation
Feb 12, 2026, 06:30 ET Restaurant Brands International Inc. Reports Fourth Quarter and Full Year 2025 Results
pressures and currency fluctuations on our and our franchisees' results of operations and business; (ii) our remodel program and refranchising efforts; (iii) leverage and free cash flow; (iv) our and our franchisees' future operational and financial performance, and our effective tax rates and adjusted net
More news about: Restaurant Brands International Inc.
Feb 12, 2026, 06:30 ET Restaurant Brands International Inc. Reports Fourth Quarter and Full Year 2025 Results
pressures and currency fluctuations on our and our franchisees' results of operations and business; (ii) our remodel program and refranchising efforts; (iii) leverage and free cash flow; (iv) our and our franchisees' future operational and financial performance, and our effective tax rates and adjusted net
More news about: Restaurant Brands International Inc.
Feb 12, 2026, 06:00 ET Gogoro Releases Fourth Quarter and Full Year 2025 Financial Results
upgrade initiatives primarily due to the completion of our upgrade program this quarter, (ii) a $0.3 million reduction in share-based compensation, (iii) a $2.0 million reduction in inventory write-downs resulting from more effective inventory management and optimization, (iv) costs at overseas entities
More news about: Gogoro
Feb 12, 2026, 05:30 ET Real-World Evidence: Improved Pain and Function Scores Reported in Posterior Tibial Tendon Degeneration
processing company specializing in compliant human connective tissue allografts. Wharton's Jelly is a perinatal connective tissue rich in collagen types I, III, and V, hyaluronic acid, proteoglycans, and other extracellular matrix components structurally analogous to tendon tissue."This publication reflects
More news about: Regenative Labs
Feb 12, 2026, 02:50 ET Recommended Cash Acquisition of Schroders plc by Nuveen, LLC
expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; (iii) business and management strategies and the expansion and growth of Nuveen's or TIAA Group's operations and potential synergies resulting from the Transaction;
More news about: Nuveen
Feb 11, 2026, 22:06 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
of the case: According to the lawsuit, defendants provided investors with material information concerning Ultragenyx's expected results for its Phase III Orbit and Cosmic Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other
More news about: THE ROSEN LAW FIRM, P. A.
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
against both common and uncommon EGFR alterations, including PACC and exon 20 insertion mutations. It is currently being investigated in a global Phase III clinical trial for first-line treatment of NSCLC patients harboring EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase Ib
More news about: DelveInsight Business Research, LLP
Feb 11, 2026, 17:01 ET RUSSEL METALS ANNOUNCES 2025 ANNUAL & FOURTH QUARTER RESULTS
mark-to-market on stock-based compensation; (ii) $2 million of operating losses in certain locations in Western Canada that are undergoing operational changes; (iii) $1 million expense for transaction and transition costs for the Kloeckner acquisition; (iv) $2 million expense reversal for the tariff that was recently
More news about: Russel Metals Inc.
Feb 11, 2026, 17:01 ET Sun Life Reports Fourth Quarter and Full Year 2025 Results
foreign exchange translation; and(iii)an increase of $5.0 billion primarily from business
More news about: Sun Life Financial Inc. - Financial News
Feb 11, 2026, 17:01 ET Sun Life Reports Fourth Quarter and Full Year 2025 Results
foreign exchange translation; and(iii)an increase of $5.0 billion primarily from business
More news about: Sun Life Financial Inc. - Financial News
Feb 11, 2026, 16:06 ET STAG INDUSTRIAL ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 RESULTS
a renewal of the same space as the current lease at lease expiration, (ii) a renewal of only a portion of the current space at lease expiration, or (iii) an early renewal or workout, which ultimately does extend the original term for 12 months or more.Repositioning: We define Repositioning
More news about: STAG Industrial, Inc.
Feb 11, 2026, 16:01 ET Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Wegovy® (semaglutide). A Phase III clinical program is anticipated to be initiated in the first half of 2026.Imsidolimab Biologics License Application (BLA) in generalized pustular psoriasis (GPP) was submitted to the FDA in the fourth quarter of 2025.A Phase III study of VQW-765, an alpha-7
More news about: Vanda Pharmaceuticals Inc.
Feb 11, 2026, 12:16 ET Swarm Defense Selected for $1.1 Billion U.S. Drone Dominance Program
maintaining mission effectiveness."Phase I focuses on individual drone performance," said Adam Wright, President and former Navy SEAL. "But Phases III and IV explicitly require operators to control multiple drones simultaneously—that's where our technology becomes decisive. Our deconfliction algorithm
More news about: Swarm Defense
Feb 11, 2026, 09:30 ET Global X Expands Commodity Line-Up; New Fund Invests in Physical Commodity Exchange-Traded Products and Futures Contracts
[email protected][i] Source: Global X ETFs, as of February 6, 2026.[ii] Source: Global X ETFs, as of December 31, 2025.[iii] Source: Mirae Asset, as of December 31, 2025.
More news about: Global X Management Company LLC
Feb 11, 2026, 09:28 ET Marco's Pizza Earns Top 10 FUND® Score Nationally, Ranked No. 1 Among All QSR and Pizza Brands
This information excludes (i) international locations (including Puerto Rico); (ii) Franchised Stores not open for the entire 52-week period in 2024; (iii) special venue and non-traditional franchised locations; and (iv) Franchised Stores that closed in 2024. See Item 19 of our 2025 Franchise Disclosure
More news about: Marco's Pizza
Feb 11, 2026, 09:15 ET Big Tree Cloud Holdings Limited Announces Implementation of Class A/B Share Structure and 1-for-20 Share Consolidation
registered in the names of various shareholders be redesignated as 1,251,873 issued class A ordinary shares of US$0.002 each;(iii) the 18,748,127 authorised but unissued ordinary shares of par value of US$0.002 each in the capital of the Company be redesignated as 18,748,127 authorised
More news about: Big Tree Cloud Holdings Limited
Feb 11, 2026, 09:15 ET Latch (Now DOOR) Files Q3 2025 SEC Report and Provides Q3 2025 Financial Update
net loss, excluding the impact of the following items, if applicable: (i) depreciation and amortization expense, (ii) net interest income or expense, (iii) provision for income taxes, (iv) change in fair value of warrant liability, trading securities, or derivative instruments, (v) restructuring costs,
More news about: DOOR
Feb 11, 2026, 09:10 ET PLUG SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Plug Power (PLUG) Investors of Securities Class Action Deadline on April 3, 2026
facilities necessary to receive those funds; (ii) as such, Plug Power was likely to pivot toward more modest projects with less commercial upside; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.On October 7, 2025, Plug Power issued
More news about: Faruqi & Faruqi, LLP
Feb 11, 2026, 09:06 ET RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate ("AFR"), such that the second interim analysis could be performed and presented to the investing public; and (ii) in truth, Ultragenyx' optimism in the Phase III Orbit study's results
More news about: Faruqi & Faruqi, LLP
Feb 11, 2026, 09:02 ET New York City Surgeon Dr. Mark P. Zoland to Present on Core Muscle Injuries at Hospital for Special Surgery Soccer Medicine Symposium
and Rehabilitation of Soccer Athletes" symposium. The event, scheduled for March 27, 2026, from 9:00 AM to 12:30 PM, will be led by Riley J. Williams III, MD, Chief of the Sports Medicine Institute at Hospital for Special Surgery and Head Team Physician for the New York Red Bulls. Dr. Zoland's
More news about: Core Surgical
Feb 11, 2026, 09:00 ET Levi & Korsinsky Notifies Shareholders of Ultragenyx Pharmaceutical Inc.(RARE) of a Class Action Lawsuit and an Upcoming Deadline
decrease in annualized fracture rates or otherwise the Phase III Orbit and Cosmic studies were much less likely to be able to demonstrate such a link than management claimed. On December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies had not "achieved statistical significance
More news about: Levi & Korsinsky, LLP